Inovio Pharmaceuticals, Inc. (AMEX: INO) reported Q3 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $2.64 million versus the consensus estimate of $1.87 million.

Earnings